# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao reiterates Evotec (NASDAQ:EVO) with a Buy and maintains $11 price target.
Evotec (NASDAQ:EVO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 35 p...
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies...
Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic co...
HC Wainwright & Co. analyst Douglas Tsao maintains Evotec (NASDAQ:EVO) with a Buy and lowers the price target from $14 t...